Teva Claims Diovan 180-Day Exclusivity, Arguing Ranbaxy ANDA Was Incomplete
This article was originally published in The Pink Sheet Daily
Teva supports citizen petition claiming Ranbaxy is ineligible for exclusivity but says that it is the actual first ANDA filer; generic has yet to launch nearly two years after Novartis’ Diovan patents expired.
You may also be interested in...
In a suit against FDA, Mylan argues that Ranbaxy’s delay in getting tentative approval for its valsartan ANDA within 30 months of submission triggered forfeiture of its 180-day marketing exclusivity.
Pink Sheet reporter and editors discuss the FDA acknowledging reports of malignancies in patients who received CAR-T cell immunotherapies, the agency’s policy for using background music in direct-to-consumer advertising, and the FDA’s new incoming principal deputy commissioner.
People have challenged patent listings more than 60 times in the past six years but it is up to new drug application holders to decide whether to revise or delist their submissions.